Liminatus Pharma Class Stock Price Patterns
| LIMN Stock | 1.84 0.21 10.24% |
Momentum 48
Impartial
Oversold | Overbought |
Using Liminatus Pharma hype-based prediction, you can estimate the value of Liminatus Pharma Class from the perspective of Liminatus Pharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Liminatus Pharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Liminatus because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Liminatus Pharma after-hype prediction price | USD 1.82 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Liminatus | Build AI portfolio with Liminatus Stock |
Liminatus Pharma After-Hype Price Density Analysis
As far as predicting the price of Liminatus Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Liminatus Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Liminatus Pharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Liminatus Pharma Estimiated After-Hype Price Volatility
In the context of predicting Liminatus Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Liminatus Pharma's historical news coverage. Liminatus Pharma's after-hype downside and upside margins for the prediction period are 0.09 and 17.64, respectively. We have considered Liminatus Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Liminatus Pharma is out of control at this time. Analysis and calculation of next after-hype price of Liminatus Pharma Class is based on 3 months time horizon.
Liminatus Pharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Liminatus Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Liminatus Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Liminatus Pharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.89 | 15.82 | 0.02 | 0.07 | 6 Events / Month | 6 Events / Month | In about 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
1.84 | 1.82 | 1.09 |
|
Liminatus Pharma Hype Timeline
Liminatus Pharma Class is now traded for 1.84. The entity has historical hype elasticity of -0.02, and average elasticity to hype of competition of 0.07. Liminatus is expected to decline in value after the next headline, with the price expected to drop to 1.82. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -1.09%, whereas the daily expected return is now at 1.89%. The volatility of related hype on Liminatus Pharma is about 40564.1%, with the expected price after the next announcement by competition of 1.91. About 83.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.16. Liminatus Pharma Class had not issued any dividends in recent years. Given the investment horizon of 90 days the next expected press release will be in about 6 days. Check out Liminatus Pharma Basic Forecasting Models to cross-verify your projections.Liminatus Pharma Related Hype Analysis
Having access to credible news sources related to Liminatus Pharma's direct competition is more important than ever and may enhance your ability to predict Liminatus Pharma's future price movements. Getting to know how Liminatus Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Liminatus Pharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ATHE | Alterity Therapeutics | (0.06) | 8 per month | 0.00 | (0.10) | 5.71 | (7.44) | 17.55 | |
| NNVC | NanoViricides | 0.02 | 7 per month | 0.00 | (0.16) | 7.69 | (8.20) | 34.35 | |
| GBIO | Generation Bio Co | 0.01 | 10 per month | 1.98 | 0.02 | 3.39 | (3.99) | 12.30 | |
| MURA | Mural Oncology Plc | 0.02 | 5 per month | 0.00 | (0.1) | 0.96 | (0.48) | 4.78 | |
| EVAX | Evaxion Biotech AS | 0.91 | 9 per month | 0.00 | (0.16) | 9.15 | (8.42) | 37.88 | |
| BTAI | BioXcel Therapeutics | 0.01 | 7 per month | 0.00 | (0.1) | 8.90 | (8.05) | 22.34 | |
| JSPR | Jasper Therapeutics | (0.56) | 11 per month | 0.00 | (0.14) | 7.73 | (9.04) | 31.75 | |
| DYAI | Dyadic International | (0.01) | 10 per month | 0.00 | (0.11) | 6.82 | (6.32) | 16.34 | |
| SABS | SAB Biotherapeutics | (0.03) | 9 per month | 3.28 | 0.09 | 6.13 | (4.94) | 22.52 | |
| MAIA | MAIA Biotechnology | 0.08 | 11 per month | 7.41 | 0.12 | 12.60 | (10.75) | 45.94 |
Liminatus Pharma Additional Predictive Modules
Most predictive techniques to examine Liminatus price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Liminatus using various technical indicators. When you analyze Liminatus charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Liminatus Pharma Predictive Indicators
The successful prediction of Liminatus Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Liminatus Pharma Class, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Liminatus Pharma based on analysis of Liminatus Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Liminatus Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Liminatus Pharma's related companies.
Pair Trading with Liminatus Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Liminatus Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Liminatus Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Liminatus Stock
| 0.66 | JEF | Jefferies Financial | PairCorr |
| 0.62 | CVNA | Carvana | PairCorr |
| 0.58 | NVO | Novo Nordisk AS | PairCorr |
| 0.57 | NONOF | Novo Nordisk AS | PairCorr |
| 0.55 | INDV | Indivior PLC Ordinary Earnings Call This Week | PairCorr |
| 0.55 | UNF | Unifirst | PairCorr |
The ability to find closely correlated positions to Liminatus Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Liminatus Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Liminatus Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Liminatus Pharma Class to buy it.
The correlation of Liminatus Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Liminatus Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Liminatus Pharma Class moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Liminatus Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Liminatus Pharma Basic Forecasting Models to cross-verify your projections. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Will Biotechnology sector continue expanding? Could Liminatus diversify its offerings? Factors like these will boost the valuation of Liminatus Pharma. Expected growth trajectory for Liminatus significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Liminatus Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.16) |
Liminatus Pharma Class's market price often diverges from its book value, the accounting figure shown on Liminatus's balance sheet. Smart investors calculate Liminatus Pharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Liminatus Pharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Liminatus Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Liminatus Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Liminatus Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.